These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 28777668)
1. Therapeutic Tumor Control of HER2 DNA Vaccines Is Achieved by an Alteration of Tumor Cells and Tumor Microenvironment by Gemcitabine and Anti-Gr-1 Ab Treatment in a HER2-Expressing Tumor Model. Danishmalik SN; Sin JI DNA Cell Biol; 2017 Sep; 36(9):801-811. PubMed ID: 28777668 [TBL] [Abstract][Full Text] [Related]
2. Tumor regression is mediated via the induction of HER263-71- specific CD8+ CTL activity in a 4T1.2/HER2 tumor model: no involvement of CD80 in tumor control. Nilofar Danishmalik S; Lee SH; Sin JI Oncotarget; 2017 Apr; 8(16):26771-26788. PubMed ID: 28460461 [TBL] [Abstract][Full Text] [Related]
3. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452 [TBL] [Abstract][Full Text] [Related]
4. Optimized Gemcitabine Therapy in Combination with E7 Peptide Immunization Elicits Tumor Cure by Preventing Ag-Specific CTL Inhibition in Animals with Large Established Tumors. Jang HY; Han BS; Kwon B; Sin JI DNA Cell Biol; 2018 Oct; 37(10):850-860. PubMed ID: 30227079 [TBL] [Abstract][Full Text] [Related]
5. A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model. Ahn E; Kim H; Han KT; Sin JI Cancer Lett; 2015 Jan; 356(2 Pt B):676-85. PubMed ID: 25449428 [TBL] [Abstract][Full Text] [Related]
6. Regulation of the translation activity of antigen-specific mRNA is responsible for antigen loss and tumor immune escape in a HER2-expressing tumor model. Han BS; Ji S; Woo S; Lee JH; Sin JI Sci Rep; 2019 Feb; 9(1):2855. PubMed ID: 30814560 [TBL] [Abstract][Full Text] [Related]
7. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Ko HJ; Kim YJ; Kim YS; Chang WS; Ko SY; Chang SY; Sakaguchi S; Kang CY Cancer Res; 2007 Aug; 67(15):7477-86. PubMed ID: 17671218 [TBL] [Abstract][Full Text] [Related]
8. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085 [TBL] [Abstract][Full Text] [Related]
9. Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy. Zhang X; Liang Q; Cao Y; Yang T; An M; Liu Z; Yang J; Liu Y J Nanobiotechnology; 2024 Jun; 22(1):319. PubMed ID: 38849938 [TBL] [Abstract][Full Text] [Related]
10. Jung KH; Park JW; Lee JH; Moon SH; Cho YS; Lee KH J Nucl Med; 2021 May; 62(5):656-664. PubMed ID: 32917780 [TBL] [Abstract][Full Text] [Related]
11. Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state. Tongu M; Harashima N; Tamada K; Chen L; Harada M Cancer Sci; 2015 Jan; 106(1):9-17. PubMed ID: 25363339 [TBL] [Abstract][Full Text] [Related]
12. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors. Salewski I; Henne J; Engster L; Schneider B; Lemcke H; Skorska A; Berlin P; Henze L; Junghanss C; Maletzki C Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206051 [TBL] [Abstract][Full Text] [Related]
13. Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity. Whittington PJ; Radkevich-Brown O; Jacob JB; Jones RF; Weise AM; Wei WZ Cancer Immunol Immunother; 2009 May; 58(5):759-67. PubMed ID: 18836716 [TBL] [Abstract][Full Text] [Related]
14. Combined stimulation of IL-2 and 4-1BB receptors augments the antitumor activity of E7 DNA vaccines by increasing Ag-specific CTL responses. Kim H; Kwon B; Sin JI PLoS One; 2013; 8(12):e83765. PubMed ID: 24391824 [TBL] [Abstract][Full Text] [Related]
15. Tumor Microenvironment following Gemcitabine Treatment Favors Differentiation of Immunosuppressive Ly6C Wu C; Tan X; Hu X; Zhou M; Yan J; Ding C J Immunol; 2020 Jan; 204(1):212-223. PubMed ID: 31776206 [TBL] [Abstract][Full Text] [Related]
16. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. Deng L; Liang H; Burnette B; Beckett M; Darga T; Weichselbaum RR; Fu YX J Clin Invest; 2014 Feb; 124(2):687-95. PubMed ID: 24382348 [TBL] [Abstract][Full Text] [Related]
17. Synergistic tumoricidal effect of combined hPD-L1 vaccine and HER2 gene vaccine. Zhang W; Wang S; Gu J; Gao Y; Wang Z; Zhang K; Mu N; Huang T; Li W; Hao Q; Xue X; Zhang W; Zhang Y; Zhang C Biochem Biophys Res Commun; 2018 Feb; 497(1):394-400. PubMed ID: 29438713 [TBL] [Abstract][Full Text] [Related]
18. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Tongu M; Harashima N; Monma H; Inao T; Yamada T; Kawauchi H; Harada M Cancer Immunol Immunother; 2013 Feb; 62(2):383-91. PubMed ID: 22926062 [TBL] [Abstract][Full Text] [Related]
19. CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models. Lv Z; Zhang P; Li D; Qin M; Nie L; Wang X; Ai L; Feng Z; Odhiambo WO; Ma Y; Ji Y Oncoimmunology; 2020; 9(1):1747688. PubMed ID: 32363119 [TBL] [Abstract][Full Text] [Related]
20. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes. Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]